 Additionally, Titanocene Y is able to induce apoptosis via the FAS receptor pathway.Very encouraging is the fact that Titanocene Y is breaking platinum-resistance in human colon and human lung cancer cells, which might make it attractive as a cytotoxic component of future 2nd or 3rd line cancer treatments.Titanocene Y was tested extensively "in vivo"; it showed promising results against xenografted human epidermoid carcinoma and prostate cancer, while best results are reached against breast and renal-cell cancer.